Sionna Therapeutics, Inc. (SION)
NASDAQ: SION · Real-Time Price · USD
22.81
-0.99 (-4.16%)
At close: Sep 12, 2025, 4:00 PM EDT
22.83
+0.02 (0.09%)
After-hours: Sep 12, 2025, 5:42 PM EDT
Sionna Therapeutics Employees
Sionna Therapeutics had 41 employees as of December 31, 2024. The number of employees increased by 13 or 46.43% compared to the previous year.
Employees
41
Change (1Y)
13
Growth (1Y)
46.43%
Revenue / Employee
n/a
Profits / Employee
-$1,849,732
Market Cap
1.01B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 41 | 13 | 46.43% |
| Dec 31, 2023 | 28 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
SION News
- 3 days ago - Stock Picks From Seeking Alpha's August 2025 New Analysts - Seeking Alpha
- 5 days ago - Sionna Therapeutics, Inc. (SION) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript) - Seeking Alpha
- 5 days ago - Sionna Therapeutics Appoints Caroline Stark Beer as Chief Business Officer - GlobeNewsWire
- 17 days ago - Sionna Therapeutics to Participate in Upcoming September Investor Conferences - GlobeNewsWire
- 19 days ago - Sionna Therapeutics Announces First Subjects Dosed in Phase 1 Trial Evaluating NBD1 Stabilizer, SION-451, in Proprietary Dual Combinations in Development for the Treatment of Cystic Fibrosis - GlobeNewsWire
- 4 weeks ago - Sionna Therapeutics Reports Second Quarter 2025 Financial Results - GlobeNewsWire
- 3 months ago - Sionna Therapeutics Announces Presentation of Preclinical Data that Demonstrate Proprietary Dual Combination Therapies Enable Full CFTR Correction in CFHBE Model - GlobeNewsWire
- 3 months ago - Sionna Therapeutics Announces Positive Phase 1 Data for NBD1 Stabilizers SION-719 and SION-451 and Advances Both Programs in Clinical Development for Cystic Fibrosis - GlobeNewsWire